Compare Regeneron Pharmaceuticals Inc (REGN) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Weibo Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Weibo Corp trades at $6.46 (market cap $1.57B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 48.7× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.41%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Weibo Corp for 102 Days on average.
| REGN | WB | |
|---|---|---|
Market Cap | $76.40B | $1.57B |
Volume | 626,381 | 947,144 |
Sector | Health | Media |
52-Week High | $852.03 | $12.37 |
52-Week Low | $557.73 | $6.33 |
Typical Hold Time | 107 Days | 102 Days |
Enterprise Value | $71.12B | $799.15M |
Dividend Yield | 0.51% | 9.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Weibo (WB) trades at $6.44, down 0.77% on the day, with a bearish technical signal from moving averages. The stock shows attractive valuation metrics with a P/E of 5.36 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins and 17.78% net income margin. Recent Q2 2026 earnings beat expectations with $0.38 EPS versus $0.36 expected, though Q1 and Q4 2025 missed estimates. Cash flow trends show volatility, with 2024 net cash flow negative $694 million but improving to positive $408 million in 2025.
Weibo presents a deep-value opportunity with compelling valuation multiples, though growth concerns persist amid declining user metrics and advertising revenue challenges. Analyst sentiment remains mixed with 41% buy ratings versus 45% hold, reflecting uncertainty about the company's ability to maintain relevance against intensifying competition. Key risks include stagnating user growth and advertising market pressures, while the current price offers margin of safety for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
